We found that the risk of MI in current users of estrogen and estrogen-progestin was nearly the same in women with no, one, two, and three major CHD risk factors. Confidence intervals remain wide even when risk factors were grouped according to their number.
1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998; 280: 605–613.
2. Adam S, Williams V, Vessey M. Cardiovascular disease and hormone replacement treatment: a pilot case-control study. BMJ 1981; 282: 1277–1278.
3. Avila MH, Walker AM, Jick H. Use of replacement estrogens and the risk of myocardial infarction. Epidemiology 1990; 1: 128–133.
4. Bain C, Willett WC, Hennekens CH, Rosner B, Belanger C, Speizer FE. Use of postmenopausal hormones and risk of myocardial infarction. Circulation 1981; 64: 42–46.
5. Bush TL, Barrett-Connor E, Cowan LD, Criqui MH, Wallace RB, Suchindran CM, Tyroler HA, Rifkind BM. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102–1109.
6. Byrd BF, Burch JC, Vaughn WK. The impact of long term estrogen support after hysterectomy. A report of 1016 cases. Ann Surg 1977; 185: 574–580.
7. Criqui MH, Suarez L, Barrett-Connor E, McPhillips J, Wingard DL, Garland C. Postmenopausal estrogen use and mortality: results from a prospective study in a defined, homogenous community. Am J Epidemiol 1988; 128: 606–614.
8. Ettinger B, Friedman GD, Bush T, Quesenberry CP Jr. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87: 6–12.
9. Falkeborn M, Persson I, Adami H-O, Bergstrom R, Eaker E, Lithell H, Mohsen R, Naessen T. The risk of acute myocardial infarction after oestrogen and oestrogen-progestogen replacement. Br J Obstet Gynaecol 1992; 99: 821–828.
10. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453–461. [Published erratum appears in N Engl J Med 1996;335:1406].
11. Hammond CB, Jelovesk FR, Lee KL, Creasman WT, Parker RT. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 1979; 133: 525–536.
12. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991; 151: 75–78.
13. MacMahon B. Cardiovascular disease and noncontraceptive oestrogen therapy. In: Oliver MF, ed. Coronary Heart Disease in Young Women. New York: Churchill Livingston, 1978; 197–207.
14. Mann RD, Lis Y, Chukwujindy J, Chanter DO. A study of the association between hormone replacement therapy, smoking and occurrence of myocardial infarction in women. J Clin Epidemiol 1994; 47: 307–312.
15. O’Brien JE, Peterson ED, Keeler GP, Berdan LG, Ohman EM, Faxon DP, Jacobs AK, Topol EJ, Califf RM. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996; 28: 1111–1118.
16. O’Keefe JH, Kim SC, Hall RR, Cochran VC, Lawhorn SL, McCallister BD. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997; 29: 1–5.
17. Petitti DB, Perlman JA, Sidney S. Noncontraceptive estrogens and mortality: long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol 1987; 70: 289–293.
18. Pfeffer RI, Whipple GH, Kurosaki TT, Chapman JM. Coronary risk and estrogen use in postmenopausal women. Am J Epidemiol 1978; 107: 479–487.
19. Psaty BM, Heckbert SR, Atkins D, Lemaitre R, Koepsell TD, Wahl PW, Siscovick DS, Wagner EH. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994; 154: 1333–1339.
20. Rosenberg L, Armstrong B, Jick H. Myocardial infarction and estrogen therapy in post-menopausal women. N Engl J Med 1976; 294: 1256–1259.
21. Rosenberg L, Palmer JR, Shapiro S. A case-control study of myocardial infarction in relation to use of estrogen supplements. Am J Epidemiol 1993; 137: 54–63.
22. Ross RK, Paganini-Hill A, Mack TM, Arthur M, Henderson BE. Menopausal oestrogen therapy and protection from death from ischemic heart disease. Lancet 1981; 1: 858–860.
23. Sidney S, Petitti DB, Quesenberry CP. Myocardial infarction and the use of estrogen and estrogen-progestogen in postmenopausal women. Ann Intern Med 1997; 127: 501–508.
24. Sullivan JM, El-Zeky F, Vander Zwaag R, Ramanathan KB. Effect on survival of estrogen replacement therapy after coronary artery bypass grafting. Am J Cardiol 1997; 79: 847–850.
25. Sullivan JM, Vander Zwaag R, Hughes JP, Maddock V, Kroetz FW, Ramanathan KB, Mirvis DM. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990; 150: 2257–2562.
26. Talbott E, Kuller LH, Detre K, Perper J. Biologic and psychosocial risk factors of sudden death from coronary disease in white women. Am J Cardiol 1977; 39: 858–864.
27. Petitti DB. Hormone replacement therapy and heart disease prevention: experimentation trumps observation. JAMA 1998; 280: 651–653.
28. Col NF, Eckman MH, Karas RH, Pauker SG, Goldberg RJ, Ross EM, Orr RK, Wong JG. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA 1997; 277: 1140–1147.
29. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, Ernster VL, Cummings SR. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016–1037.
30. Gillum RF, Fortmann S, Prineas RJ, Kottke TE. International diagnostic criteria for myocardial infarction and acute stroke. (Prepared for the Committee on Criteria and Methods, Council on Epidemiology, American Heart Association). Am Heart J 1984; 108: 150–158.
31. Gillum RF. Cardiovascular disease in the United States: an epidemiologic overview. In: Saunders E, Brest AN, eds. Cardiovascular Diseases in Blacks. Philadelphia: FA Davis, 1991; 3–16.
32. The Women’s Health Initiative Study Group. Design of the Women’s Health Initiative clinical trial and observational study. Control Clin Trials 1998; 19: 61–109.